Granules India Ltd-$ — earnings calls

Granules India reported Q1 FY27 revenue of about Rs 1,477 crore, up 22% year-on-year, with EBITDA growing 37% to Rs 339 crore and profit after tax up 60% to Rs 180 crore. Management said complex generics now form about 50% of finished dosages compared to 39% a year earlier, and the peptide CDMO business grew more than 100% year-on-year. The company also stated that remediation work at its Gagillapur facility is essentially complete, with the FDA having raised no concerns on the pace or adequacy of corrective actions to date.

Granules India reported FY26 revenue of INR53,656 million, up 20% year-on-year, with EBITDA growing 25% to INR11,851 million and margins expanding to 22.1%. Q4 FY26 saw the peptide CDMO business, Ascelis/Senn Chemicals, turn EBITDA positive for the first time, while net debt reduced to INR4,021 million from INR7,061 million. Management described progress on U.S. FDA remediation at Gagillapur, regulatory inspections at other sites, and continued expansion of the finished dosage and complex generics portfolio.